| Literature DB >> 15774044 |
Pedro Paulo S Soares1, Adalgiza M Moreno, Sérgio L D Cravo, Antonio Claudio L Nóbrega.
Abstract
INTRODUCTION: Imbalance in autonomic cardiovascular function increases the risk for sudden death in patients with coronary artery disease (CAD), but the time course of the impact of coronary artery bypass grafting (CABG) on autonomic function has been little studied. Thus, the purpose of the present study was to determine the effects of the CABG on the cardiovascular autonomic function.Entities:
Mesh:
Year: 2005 PMID: 15774044 PMCID: PMC1175925 DOI: 10.1186/cc3042
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Demographic characteristics of patients and control subjects
| Characteristic | CABG ( | CAD ( | Healthy ( |
| Sex (males/females) | 8/5 | 5/4 | 4/5 |
| Age (years) | 64 ± 2 | 64 ± 2 | 63 ± 2 |
| Body mass index (kg/m2) | 27.6 ± 0.6 | 27.4 ± 0.7 | 26.5 ± 0.9 |
| Drug used | |||
| ACE inhibitors/AngioII-blockers | 5 | 6 | - |
| Digital | 3 | 0 | - |
| Anti-arrhythmic | 1 | 0 | - |
| β-blockers | 6 | 1 | - |
| Calcium-channel antagonists | 4 | 1 | - |
| AAS | 7 | 3 | - |
Values are means ± SEM. AAS, acetylsalicylic acid; ACE, angiotensin-converting enzyme; CABG, patients who underwent coronary artery bypass grafting; CAD, patients with coronary artery disease who did not undergo surgery; healthy, control subjects without CAD. The three groups were similar with regard to all variables (P > 0.05).
Figure 1Longitudinal evaluation of autonomic cardiovascular tests in patients undergoing coronary artery bypass grafting surgery. Longitudinal autonomic cardiovascular evaluation (Valsalva maneuver and respiratory sinus arrhythmia) in the three groups: CABG, patients who underwent coronary artery bypass grafting; CAD, patients with coronary artery disease who did not undergo surgery; healthy, control subjects without CAD. *P < 0.05 versus CABG preoperative value; †P < 0.05 versus CABG day 3; ‡P < 0.05 versus CABG and CAD.
Time-domain indexes of heart rate variability before and at various intervals after coronary artery bypass grafting
| Variable | Group | Preoperative | After surgery | |||||
| 3 days | 6 days | 15 days | 30 days | 60 days | 90 days | |||
| Mean R–R (ms) | CABG | 903 ± 40 | 761 ± 45* | 781 ± 42* | 790 ± 36* | 802 ± 26* | 801 ± 36 | 802 ± 35 |
| CAD | 856 ± 49 | - | - | - | 842 ± 38 | 816 ± 33 | 835 ± 47 | |
| Healthy | 860 ± 36 | - | - | - | - | - | - | |
| SDNN (ms) | CABG | 35 ± 3 | 16 ± 2* | 16 ± 2* | 19 ± 2* | 25 ± 2* | 32 ± 3 | 27 ± 3 |
| CAD | 31 ± 4 | - | - | - | 29 ± 3 | 30 ± 3 | 31 ± 2 | |
| Healthy | 42 ± 5† | - | - | - | - | - | - | |
| SDANN (ms) | CABG | 16 ± 3 | 6 ± 1* | 6 ± 1* | 9 ± 1* | 15 ± 3 | 18 ± 3 | 14 ± 2 |
| CAD | 21 ± 4 | - | - | - | 19 ± 3 | 20 ± 3 | 20 ± 3 | |
| Healthy | 39 ± 7† | - | - | - | - | - | - | |
| RMSSD (ms) | CABG | 24 ± 4 | 10 ± 2* | 10 ± 1* | 12 ± 1* | 19 ± 4 | 21 ± 3 | 19 ± 2 |
| CAD | 22 ± 3 | - | - | - | 18 ± 3 | 19 ± 2 | 20 ± 4 | |
| Healthy | 27 ± 3 | - | - | - | - | - | - | |
| pNN50 (%) | CABG | 8 ± 0 | 3 ± 0* | 3 ± 0* | 3 ± 0* | 4 ± 0* | 7 ± 0 | 6 ± 0 |
| CAD | 4 ± 0 | - | - | - | 3 ± 0 | 4 ± 0 | 3 ± 0 | |
| Healthy | 11 ± 0b | - | - | - | - | - | - | |
Values are means ± SEM. *P < 0.05 versus CABG preoperative value; †P < 0.05 versus CABG and CAD. CABG, patients who underwent coronary artery bypass grafting; CAD, patients with coronary artery disease who did not undergo surgery; healthy, control subjects without CAD; pNN50, percentage number of pairs of adjacent R–R intervals differing by more than 50 ms; RMSSD, square root of the mean of squares of differences between adjacent R–R intervals; SDANN, standard deviation of the averages of the R–R intervals calculated in 5-minute segments; SDNN, standard deviation of all R–R intervals.
Figure 2Longitudinal evaluation of heart rate variability in patients undergoing coronary artery bypass grafting surgery. Longitudinal results of spectral analysis of heart rate variability in the three groups: CABG, patients who underwent coronary artery bypass grafting; CAD, patients with coronary artery disease who did not undergo surgery; healthy, control subjects without CAD. Total power (a) and low-frequency power (b) indicate both adrenergic and parasympathetic modulation of heart rate; high-frequency power (c) represents the parasympathetic component; and the low-frequency/high-frequency ratio (d) represents autonomic balance that modulates heart rate. *P < 0.05 versus CABG preoperative value; †P < 0.05 versus CABG day 3 or 6; ‡P < 0.05 versus CABG and CAD, except high frequency, for which ‡P < 0.05 versus CAD.